Response indication

Home / Response indication

Response indication

BSI is suggested for the development of a treatment response indicator in prostate cancer.

On-treatment change in BSI is demonstrated to be associated with overall survival in patients with metastatic castration-resistant prostate cancer on immunomodulator- or chemotherapy. [1][2][3][4]

Patients on immunomodulator treatment (Tasq) showed a slower BSI-increase than patients on the placebo. [1]

Patients on (Tasq) showed a slower BSI-increase than patients on the placebo. [1]

Patients with decreased BSI (pink line) while on chemotherapy survived longer than patients with increased BSI (blue line). [2]

Patients with decreased BSI (pink line) while on survived longer than patients with increased BSI (blue line). [2]

The relationship between the median survival time (days) and the percent change of BSI (from baseline to 6 months) suggests that decreased BSI is associated with an increased survival time for patients on chemotherapy. [3]

The relationship between the median survival time (days) and the percent change of BSI (from baseline to 6 months) suggests that decreased BSI is associated with an increased survival time for patients on . [3]

Decreased BSI for patients on chemotherapy was associated with an increased overall survival probability. [4]

Decreased BSI for patients on was associated with an increased overall survival probability. [4]

[1]

Armstrong AJ, Kaboteh R, Carducci MA, et al. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). Urol Oncol 2014 Sep 15. pii: S1078-1439(14)00283-X. doi: 10.1016/j.urolonc.2014.08.006. [Epub ahead of print]

[2]

Mitsui Y, Shiina H, Yamamoto Y, et al. Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer. BJU Int 2012; 110: 628-634. doi: 10.1111/j.1464-410X.2012.11355.x

[3]

Dennis ER, Jia X, Mezheritskiy IS, et al. Bone Scan Index: A quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol 2012; 30(5): 519-524. doi: 10.1200/JCO.2011.36.5791

[4]

Kaboteh R, Gjertsson P, Leek H, Lomsky M, Ohlsson M, Sjöstrand K and Edenbrandt L. Progression of bone metastases in patients with prostate cancer - automated detection of new lesions and calculation of bone scan index. EJNMMI Research 2013, 3: 64. doi:10.1186/2191-219X-3-64